S Vercruysse1, W Vandenberghe2, L Münks1, B Nuttin3, H Devos1, A Nieuwboer1. 1. Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium. 2. Department of Neurology, University Hospitals Leuven, Leuven, Belgium. 3. Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium.
Abstract
BACKGROUND: Freezing of gait (FOG) is a debilitating gait disorder in Parkinson's disease (PD) with partial responsiveness to dopaminergic medication. To date, notions about the effects of subthalamic deep brain stimulation (STN-DBS) on FOG remain controversial. OBJECTIVES: To compare the effects of bilateral STN-DBS and continued best medical treatment (BMT) on FOG occurrence, FOG severity and clinical outcomes in PD patients at 6 and 12 months follow-up. METHODS: In this prospective, controlled study, 41 PD patients with at least 5 years disease duration participated. Twenty-four subjects (20 with FOG) were treated with STN-DBS and seventeen (15 with FOG) continued BMT. The primary outcome was the New Freezing of Gait Questionnaire (NFOGQ) at 6 months postsurgery. Other outcomes were the NFOGQ at 12 months and clinical outcomes (Unified Parkinson's Disease Rating Scale III (UPDRS III), timed gait, falls and quality of life) at both time points. RESULTS: STN-DBS increased the likelihood to convert from being a freezer to a non-freezer at 6 and 12 months follow-up (relative risk reduction=0.4). However, 45% of baseline freezers still experienced FOG 6 and 12 months postsurgery although with reduced severity. Three baseline non-freezers (1/2 BMT-treated, 2/4 STN-DBS-treated) developed FOG during follow-up. STN-DBS-induced benefits on FOG were mostly mediated by baseline levodopa equivalent dose, altered medication-intake and reduced motor fluctuations. CONCLUSIONS: In contrast to continued BMT, STN-DBS reduced FOG occurrence and severity at 6 months postsurgery with largely sustained effects at 12 months follow-up. Longer follow-up periods are needed to test whether FOG improvements after STN-DBS persist with disease progression. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: Freezing of gait (FOG) is a debilitating gait disorder in Parkinson's disease (PD) with partial responsiveness to dopaminergic medication. To date, notions about the effects of subthalamic deep brain stimulation (STN-DBS) on FOG remain controversial. OBJECTIVES: To compare the effects of bilateral STN-DBS and continued best medical treatment (BMT) on FOG occurrence, FOG severity and clinical outcomes in PDpatients at 6 and 12 months follow-up. METHODS: In this prospective, controlled study, 41 PDpatients with at least 5 years disease duration participated. Twenty-four subjects (20 with FOG) were treated with STN-DBS and seventeen (15 with FOG) continued BMT. The primary outcome was the New Freezing of Gait Questionnaire (NFOGQ) at 6 months postsurgery. Other outcomes were the NFOGQ at 12 months and clinical outcomes (Unified Parkinson's Disease Rating Scale III (UPDRS III), timed gait, falls and quality of life) at both time points. RESULTS:STN-DBS increased the likelihood to convert from being a freezer to a non-freezer at 6 and 12 months follow-up (relative risk reduction=0.4). However, 45% of baseline freezers still experienced FOG 6 and 12 months postsurgery although with reduced severity. Three baseline non-freezers (1/2 BMT-treated, 2/4 STN-DBS-treated) developed FOG during follow-up. STN-DBS-induced benefits on FOG were mostly mediated by baseline levodopa equivalent dose, altered medication-intake and reduced motor fluctuations. CONCLUSIONS: In contrast to continued BMT, STN-DBS reduced FOG occurrence and severity at 6 months postsurgery with largely sustained effects at 12 months follow-up. Longer follow-up periods are needed to test whether FOG improvements after STN-DBS persist with disease progression. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Gait; Motor Control; Movement Disorders; Neurosurgery; Parkinson's Disease
Authors: C Matzke; N Hammer; D Weise; D Lindner; D Fritzsch; J Classen; J Meixensberger; D Winkler Journal: Nervenarzt Date: 2014-12 Impact factor: 1.214
Authors: Courtney C Walton; James M Shine; Julie M Hall; Claire O'Callaghan; Loren Mowszowski; Moran Gilat; Jennifer Y Y Szeto; Sharon L Naismith; Simon J G Lewis Journal: J Neurol Date: 2014-10-16 Impact factor: 4.849
Authors: Alfonso Fasano; Camila C Aquino; Joachim K Krauss; Christopher R Honey; Bastiaan R Bloem Journal: Nat Rev Neurol Date: 2015-01-13 Impact factor: 42.937
Authors: Ali Falaki; Hang Jin Jo; Mechelle M Lewis; Barbara O'Connell; Sol De Jesus; James McInerney; Xuemei Huang; Mark L Latash Journal: Clin Neurophysiol Date: 2018-03-09 Impact factor: 3.708
Authors: Daniel Weiss; Anna Schoellmann; Michael D Fox; Nicolaas I Bohnen; Stewart A Factor; Alice Nieuwboer; Mark Hallett; Simon J G Lewis Journal: Brain Date: 2020-01-01 Impact factor: 13.501
Authors: Shervin Rahimpour; Wendy Gaztanaga; Amol P Yadav; Stephano J Chang; Max O Krucoff; Iahn Cajigas; Dennis A Turner; Doris D Wang Journal: Neuromodulation Date: 2020-12-26